ACY-738
CAS No. 1375465-91-0
ACY-738( ACY738 | ACY 738 )
Catalog No. M11552 CAS No. 1375465-91-0
ACY-738 (ACY738) is a potent and specific HDAC6 inhibitor (IC50=1.7 nM) with improved brain bioavailability; displays 60-1500 fold selectivity over class I HDACs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 53 | In Stock |
|
5MG | 87 | In Stock |
|
10MG | 159 | In Stock |
|
25MG | 267 | In Stock |
|
50MG | 438 | In Stock |
|
100MG | 582 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameACY-738
-
NoteResearch use only, not for human use.
-
Brief DescriptionACY-738 (ACY738) is a potent and specific HDAC6 inhibitor (IC50=1.7 nM) with improved brain bioavailability; displays 60-1500 fold selectivity over class I HDACs.
-
DescriptionACY-738 (ACY738) is a potent and specific HDAC6 inhibitor (IC50=1.7 nM) with improved brain bioavailability; displays 60-1500 fold selectivity over class I HDACs; induces dramatic increase in α-tubulin acetylation in brain and stimulates mouse exploratory behaviors; increases the innervation of the neuromuscular junctions in the gastrocnemius muscle and improves the motor and sensory nerve conduction in the mutant HSPB1-induced CMT2 mouse model.Depression Preclinical.
-
In VitroACY-738 (2.5?μM) increases the acetylated (lysine 40) fraction of α-tubulin in RN46A-B14 cells. ACY-738 (10 μM) induces cell death comparable to LBH589 and FK228.
-
In VivoACY-738 (5?mg/kg) leads to significant increase in α-tubulin acetylation in whole-brain lysates. ACY-738 (50?mg/kg) fails to produce an enhancement of locomotor activity in WT mice tested in a home cage environment. ACY-738 (5 mg/kg) reaches a maximum plasma concentration of 1310 ng/mL at 0.0830 h following treatment. ACY-738 (5 mg/kg BW) alters BM B cell differentiation, but shows no significant effect on IgG and C3 deposition in NZB/W mice. ACY-738 (20 mg/kg) significantly attenuates the severity of proteinuria in NZB/W F1 mice. ACY-738 (5 mg/kg) shows a significant decrease in anti-dsDNA production in NZB/W mice as they aged. ACY-738 (5, 20 mg/kg) attenuates sera IL-1β production as the NZB/W mice aged. ACY-738 (5 mg/kg) significantly reduces glomerular IL-6 and IL-10 mRNA levels by more than 50% while treatment with 20 mg/kg ACY-738 reduced IL-6 and IL-10 mRNA to non-detectable levels.
-
SynonymsACY738 | ACY 738
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC6
-
Research AreaNeurological Disease
-
IndicationDepression
Chemical Information
-
CAS Number1375465-91-0
-
Formula Weight270.2866
-
Molecular FormulaC14H14N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESO=C(C1=CN=C(NC2(C3=CC=CC=C3)CC2)N=C1)NO
-
Chemical Name5-Pyrimidinecarboxamide, N-hydroxy-2-[(1-phenylcyclopropyl)amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jochems J, et al. Neuropsychopharmacology. 2014 Jan;39(2):389-400.
2. Regna NL, et al. Clin Immunol. 2016 Jan;162:58-73.
3. Benoy V, et al. Neurotherapeutics. 2017 Apr;14(2):417-428.
molnova catalog
related products
-
Pyroxamide
Pyroxamide is an histone deacetylases (HDACs) inhibitor with antineoplastic properties ( HDAC1;IC50: 0.1-0.2 μM).
-
Resminostat
A potent inhibitor of HDAC1/3/6 with IC50s of 43-72 nM.
-
Panobinostat
A potent, broad-spectrum HDAC inhibitor with IC50 of 5-20 nM in cell-free assyas.